This newsletter presents you the following key sessions:
1. Video interview with Josep Tabernero
2. Pembrolizumab increases historic survival rate for certain people with advanced non-small cell lung cancer
3. Less toxic TPEx regimen possible new option for patients in first-line recurrent/metastatic head and neck squamous cell carcinoma
4. FOLFOXIRI + bevacizumab shows progression-free survival benefit in mCRC patients with ≥3 baseline CTCs
5. Adding apalutamide to androgen deprivation therapy prolongs survival in patients with metastatic hormone-sensitive prostate cancer